The first PPI was approved in Canada in 1988. Pronounced and durable reduction of stomach acid production made omeprazole a “blockbuster drug”, spawning multiple imitators. Eventually this included (as patent extensions) the single enantiomers esomeprazole...
Six previous Therapeutics Letters reported information about the benefits and harms of different proton pump inhibitors (PPIs).1-6 These drugs work by irreversibly inhibiting gastric H+K+ ATPase (the proton pump) in the stomach. They inhibit both basal and stimulated acid secretion...
A team of five educators with the UBC Therapeutics Initiative (Cait O'Sullivan, Pharma, Jim Wright, MD, PhD, FRCPC, Aaron Tejani, Pharma, Tom Perry, MD, FRCPC, David Urquhart, MD, CCFP) will be visiting the Kootenay Boundary Region in May to address several...